Brief: Nevro Announces Two Presentations From Clinical Trials Have Been Accepted For Late-Breaking Abstract Sessions At Nans 2023 Annual Meeting
14/12/2022 12:55
Dec 14 (Reuters) - Nevro Corp NVRO.N :
* NEVRO ANNOUNCES TWO PRESENTATIONS FROM SENZA-PDN AND
SENZA-NSRBP
CLINICAL TRIALS HAVE BEEN ACCEPTED FOR LATE-BREAKING ABSTRACT
SESSIONS AT NANS 2023 ANNUAL MEETING
Source text for Eikon: ID:nPn8FjPGsa
Further company coverage: NVRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nevro
See all newsNevro Corp reports results for the quarter ended December 31 - Earnings Summary
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro